Jazz Pharmaceuticals Public
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Jazz Pharmaceuticals Public missed slightly on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly. GAAP earnings per share increased significantly.
Gross margins dropped, operating margins dropped, net margins increased.
Jazz Pharmaceuticals Public logged revenue of $181.9 million. The 11 analysts polled by S&P Capital IQ expected revenue of $185.3 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $83.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $3.27. The 13 earnings estimates compiled by S&P Capital IQ predicted $1.41 per share. GAAP EPS of $3.27 for Q4 were 314% higher than the prior-year quarter's $0.79 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 86.0%, 940 basis points worse than the prior-year quarter. Operating margin was 36.7%, much worse than the prior-year quarter. Net margin was 109.2%, much better than the prior-year quarter.
Next quarter's average estimate for revenue is $185.8 million. On the bottom line, the average EPS estimate is $1.26.
Next year's average estimate for revenue is $809.8 million. The average EPS estimate is $5.69.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 213 members out of 278 rating the stock outperform, and 65 members rating it underperform. Among 75 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 58 give Jazz Pharmaceuticals Public a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $66.91.
- Add Jazz Pharmaceuticals Public to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.